Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne van Rongen

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Clinical Pharmacokinetics|May 9, 2018
Author's Reply to Reith: "Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen"Anne van Rongen, Pyry A J Välitalo, Catherijne A J Knibbe
Clinical Pharmacokinetics|June 25, 2018
Author's Reply to Reith: "Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults"Anne van Rongen, Johannes N van den Anker, Catherijne A J Knibbe
Expert Opinion on Drug Metabolism & Toxicology|January 12, 2022
An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision TablesAnne van Rongen, Elke Hj Krekels, Elisa Am Calvier, et al.
Pharmaceutical Research|October 14, 2025
Changes in the Fraction Metabolized in Children Younger than Four Years; When is Clearance Scaling for the Dominant Elimination Route in Adults Appropriate?Anne van Rongen, Robbin Grijseels, Elisa A M Calvier, et al.
Annual Review of Pharmacology and Toxicology|October 24, 2014
Drug disposition in obesity: toward evidence-based dosingCatherijne A J Knibbe, Margreke J E Brill, Anne van Rongen, et al.
Clinical Pharmacokinetics|March 28, 2012
Impact of obesity on drug metabolism and elimination in adults and childrenMargreke J E Brill, Jeroen Diepstraten, Anne van Rongen, et al.
British Journal of Clinical Pharmacology|June 6, 2015
Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescentsAnne van Rongen, Janelle D Vaughns, Ganesh S Moorthy, et al.
Clinical Pharmacokinetics|December 29, 2022
Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?Jeroen Diepstraten, Anne van Rongen, Marianne P Zijlstra, et al.
Pharmaceutical Research|July 24, 2015
The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric SurgeryMargreke J Brill, Anne van Rongen, Eric P van Dongen, et al.
Clinical Pharmacokinetics|May 5, 2016
Does Weight Impact Anidulafungin Pharmacokinetics?Vincent J Lempers, Anne van Rongen, Eric P van Dongen, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Clinical Pharmacokinetics|May 9, 2018
Author's Reply to Reith: "Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen"Anne van Rongen, Pyry A J Välitalo, Catherijne A J Knibbe
Clinical Pharmacokinetics|June 25, 2018
Author's Reply to Reith: "Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults"Anne van Rongen, Johannes N van den Anker, Catherijne A J Knibbe
Expert Opinion on Drug Metabolism & Toxicology|January 12, 2022
An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision TablesAnne van Rongen, Elke Hj Krekels, Elisa Am Calvier, et al.
Pharmaceutical Research|October 14, 2025
Changes in the Fraction Metabolized in Children Younger than Four Years; When is Clearance Scaling for the Dominant Elimination Route in Adults Appropriate?Anne van Rongen, Robbin Grijseels, Elisa A M Calvier, et al.
Annual Review of Pharmacology and Toxicology|October 24, 2014
Drug disposition in obesity: toward evidence-based dosingCatherijne A J Knibbe, Margreke J E Brill, Anne van Rongen, et al.
Clinical Pharmacokinetics|March 28, 2012
Impact of obesity on drug metabolism and elimination in adults and childrenMargreke J E Brill, Jeroen Diepstraten, Anne van Rongen, et al.
British Journal of Clinical Pharmacology|June 6, 2015
Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescentsAnne van Rongen, Janelle D Vaughns, Ganesh S Moorthy, et al.
Clinical Pharmacokinetics|December 29, 2022
Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?Jeroen Diepstraten, Anne van Rongen, Marianne P Zijlstra, et al.
Pharmaceutical Research|July 24, 2015
The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric SurgeryMargreke J Brill, Anne van Rongen, Eric P van Dongen, et al.
Clinical Pharmacokinetics|May 5, 2016
Does Weight Impact Anidulafungin Pharmacokinetics?Vincent J Lempers, Anne van Rongen, Eric P van Dongen, et al.
Pageof 2